NDAINTRAVENOUSPOWDER
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
TEPADINA AND SODIUM CHLORIDE (thiotepa) by Adienne Pharma and Biotech is alkylating activity [moa]. First approved in 2017.
Drug data last refreshed 23h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEPADINA is an intravenous alkylating agent containing thiotepa in powder form for reconstitution. It is indicated for hematologic malignancies and solid tumors where alkylating activity is therapeutically beneficial. Thiotepa works by covalently binding DNA, disrupting cellular replication and inducing apoptosis in rapidly dividing cancer cells.
Peak10.8 years to LOE
Peak lifecycle status indicates stable market positioning with mature commercial infrastructure, supporting mid-sized brand and field teams.
Mechanism of Action
Alkylating Activity
Pharmacologic Class:
Alkylating Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Started Dec 2006
1 enrolled
Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
Started Mar 2005
37 enrolled
Lymphoma
Career Relevance
Working on TEPADINA offers stability within a niche oncology market with established commercial operations and no near-term competitive pressure. The product's peak lifecycle status and strong patent protection provide career continuity through 2037, though limited clinical expansion opportunities may limit upward mobility tied to novel development.
Worked on TEPADINA AND SODIUM CHLORIDE at Adienne Pharma and Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.